ADHD Medication and the Risk of Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Population-Based Cohort Study
Open Access
- 16 July 2026
- journal article
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (5) , 108510
Abstract
No abstract availableFunding Information
- Karolinska Institutet
- China Scholarship Council
- Fredrik och Ingrid Thurings Stiftelse
- Hjärt-Lungfonden (20230452)
- Horizon 2020 Framework Programme
- Stiftelsen Söderström Königska Sjukhemmet
- HORIZON EUROPE Framework Programme (965381)
This publication has 7 references indexed in Scilit:
- Attention-deficit/hyperactivity disorder and cardiometabolic risk profile in patients with acute myocardial infarction: data from the SWEDEHEART registryEuropean Journal of Preventive Cardiology, 2025
- Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in AdultsJACC, 2024
- Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease studyMolecular Psychiatry, 2023
- Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart diseaseJournal of Paediatrics and Child Health, 2023
- Attention‐deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population‐based cohort studyWorld Psychiatry, 2022
- The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysisJournal of Global Health, 2021
- Accounting for missing data in statistical analyses: multiple imputation is not always the answerInternational Journal of Epidemiology, 2019